title: Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma.
abstract: Research on the biology of the tumor stroma has the potential to lead to development of more effective treatment regimes enhancing the efficacy of drug-based treatment of solid malignancies. Tumor stroma is characterized by distorted blood vessels and activated connective tissue cells producing a collagen-rich matrix, which is accompanied by elevated interstitial fluid pressure (IFP), indicating a transport barrier between tumor tissue and blood. Here, we show that the collagen-binding proteoglycan fibromodulin controls stroma structure and fluid balance in experimental carcinoma. Gene ablation or inhibition of expression by anti-inflammatory agents showed that fibromodulin promoted the formation of a dense stroma and an elevated IFP. Fibromodulin-deficiency did not affect vasculature but increased the extracellular fluid volume and lowered IFP. Our data suggest that fibromodulin controls stroma matrix structure that in turn modulates fluid convection inside and out of the stroma. This finding is particularly important in relation to the demonstration that targeted modulations of the fluid balance in carcinoma can increase the response to cancer therapeutic agents.
authors: Department of Experimental Medical Sciences, BMC, B-12, University of Lund, SE-221 84 Lund, Sweden.
authors: Ake
authors: A
authors: Oldberg
authors: Sebastian
authors: S
authors: Kalamajski
authors: Alexei V
authors: AV
authors: Salnikov
authors: Linda
authors: L
authors: Stuhr
authors: Matthias
authors: M
authors: Mörgelin
authors: Rolf K
authors: RK
authors: Reed
authors: Nils-Erik
authors: NE
authors: Heldin
authors: Kristofer
authors: K
authors: Rubin
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D003094:Collagen / Q000378:metabolism*; D045604:Extracellular Fluid / Q000502:physiology; D005109:Extracellular Matrix / Q000473:pathology / Q000648:ultrastructure; D016326:Extracellular Matrix Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D000071235:Fibromodulin; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011509:Proteoglycans / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D013964:Thyroid Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology
chemical_list: D016326:Extracellular Matrix Proteins; C000604332:Fmod protein, mouse; D011509:Proteoglycans; D000071235:Fibromodulin; D003094:Collagen
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Am J Pathol. 2000 Apr;156(4):1363-80
references: 10751361
references: Cancer Res. 2000 May 1;60(9):2497-503
references: 10811131
references: Cancer Res. 2000 Oct 1;60(19):5565-70
references: 11034104
references: J Pharmacol Exp Ther. 2001 Feb;296(2):632-41
references: 11160652
references: Biochem J. 2001 May 1;355(Pt 3):577-85
references: 11311118
references: Nature. 2001 May 17;411(6835):375-9
references: 11357145
references: Cancer Res. 2001 Aug 15;61(16):5974-8
references: 11507037
references: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9
references: 11707590
references: Nature. 2002 Jan 31;415(6871):530-6
references: 11823860
references: FASEB J. 2002 May;16(7):673-80
references: 11978731
references: Glycobiology. 2002 Sep;12(9):107R-16R
references: 12213783
references: J Biol Chem. 2002 Sep 20;277(38):35532-40
references: 12089156
references: Cancer Res. 2002 Oct 1;62(19):5476-84
references: 12359756
references: Osteoarthritis Cartilage. 2002 Oct;10(10):751-7
references: 12359160
references: Int J Cancer. 2002 Dec 10;102(5):453-62
references: 12432546
references: Nature. 2002 Dec 19-26;420(6917):860-7
references: 12490959
references: Nat Rev Immunol. 2003 Jan;3(1):23-35
references: 12511873
references: Nat Med. 2003 Jun;9(6):796-800
references: 12754503
references: Cell. 2003 Jul 11;114(1):33-45
references: 12859896
references: FASEB J. 2003 Sep;17(12):1756-8
references: 12958200
references: Clin Cancer Res. 2003 Nov 15;9(15):5508-13
references: 14654530
references: Nat Med. 2004 Feb;10(2):145-7
references: 14745444
references: Gut. 2004 Apr;53(4):581-6
references: 15016755
references: Nat Rev Cancer. 2004 Oct;4(10):806-13
references: 15510161
references: Methods Enzymol. 1982;82 Pt A:372-98
references: 7078444
references: J Biol Chem. 1986 Oct 15;261(29):13866-72
references: 3759994
references: N Engl J Med. 1986 Dec 25;315(26):1650-9
references: 3537791
references: Cancer Res. 1987 Jun 15;47(12):3039-51
references: 3555767
references: Q J Exp Physiol. 1987 Oct;72(4):409-37
references: 3321140
references: Arch Histol Cytol. 1988 Jul;51(3):249-61
references: 3140854
references: Cancer Res. 1993 Oct 15;53(20):4764-6
references: 8402656
references: J Biol Chem. 1999 Apr 2;274(14):9636-47
references: 10092650
references: Nat Rev Cancer. 2004 Nov;4(11):839-49
references: 15516957
references: Nature. 2004 Nov 18;432(7015):332-7
references: 15549095
references: J Clin Pathol. 2005 Jan;58(1):32-8
references: 15623479
references: Lab Invest. 2005 Apr;85(4):512-21
references: 15711566
references: J Immunol. 2005 Nov 15;175(10):6257-63
references: 16272275
references: Int J Cancer. 2006 Dec 15;119(12):2795-802
references: 17019708
references: Matrix Biol. 2006 Oct;25(8):484-91
references: 16979885
references: Cell. 2006 Dec 1;127(5):905-15
references: 17129778